Company Overview and News

 
Kansai Nerolac Paints Limited - Trading Window

14h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

 
Asian Paints, Kansai Nerolac down 1-2% despite Citi remains positive on revenue growth prospects

2018-09-17 moneycontrol
Paint companies including Asian Paints and Kansai Nerolac Paints were down 1-2 percent despite research house Citi remained positive on revenue growth prospects of Indian paints industry.
500820 KANSAINER KNZAY ASIANPAINT 500165

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 freepressjournal.in
New Delhi: Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER HINDUNILVR 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 500696 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 thehindubusinessline
Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

 
Kansai Nerolac Q1 net falls to Rs 139.84 cr

2018-07-21 freepressjournal.in
New Delhi : Kansai Nerolac Paints on Friday reported a marginal decline in standalone net profit at Rs 139.84 crore for the quarter ended June 30. The company had posted a net profit of Rs 140.81 crore in the year-ago period. Total income stood at Rs 1,389.52 crore.
KANSAINER KNZAY 500165

 
Kansai Nerolac Paints Q1 net at Rs 139.84 crore

2018-07-20 moneycontrol
Kansai Nerolac Paints today reported a marginal decline in its net profit at Rs 139.84 crore for the quarter ended June 30.
KANSAINER KNZAY 500165

 
Kansai Nerolac Paints Limited - Financial Result Updates

2018-07-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

 
Wipro, Bajaj Auto, MCX, HDFC Life, Ceat results

2018-07-19 thehindubusinessline
Around two dozen companies including Atul, Bajaj Auto, Bajaj Holdings, Bata India, Capital Trust, Ceat, Chowgule Steamships, Diligent Media, HDFC Standard Life Insurance, Havells India, Infomedia Press, Kansai Nerolac Paints, L&T Finance Holdings, MCX, Nelco, Onward Technologies, Radhe Developers, Ramgopal Polytex, Sanwaria Consumer, Wipro and Zee Media Corporation will declare their quarterly numbers for the period ended June 2018 on Friday.
BAJAJ-AUTO RADHEDE CHOWGULSTM 517354 501833 HVLQY ONWARDTEC KNZAY 517536 532977 BATAINDIA 531273 KANSAINER 511505 HAVELLS INFOMEDIA CAPITALT 509069 500043 500165

 
Bharat Kedia is COO at Motilal PE

2018-07-18 thehindubusinessline
SME-focussed investment firm Motilal Oswal Private Equity Investment Advisors (MOPE) has appointed Bharat Kedia as Chief Operating Officer, who was previously with Zee Entertainment Enterprises as Chief Financial Officer. In addition, he has worked in firms such as Parag Milk Foods, Publicis Groupe India, Coca-Cola HBC SA, United Beverages, BDH Industries and Kansai Nerolac Paints, earlier in his career.
CCHGY 524828 CCH KANSAINER ZEEEY KNZAY 505537 BDH ZEEL 500165

 
Kansai Nerolac Paints Limited - Trading Window

2018-07-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

4
Kansai Nerolac Paints Limited - Shareholders meeting

2018-06-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
KANSAINER KNZAY 500165

11
Kansai Nerolac Paints down 2%, to acquire 55% in RAK Paints

2018-06-20 moneycontrol
Share price of Kansai Nerolac Paints declined 2.6 percent intraday Wednesday. The company entered into share purchase agreement (SPA) to acquire 55% in RAK Paints, Bangladesh.
ICICIBANK KANSAINER KNZAY 532174 IBN 500165

11
Kansai Nerolac to acquire 55% stake in RAK Paints to enter Bangladesh

2018-06-19 moneycontrol
Paint maker Kansai Nerolac today said it is in process to acquire 55 per cent equity stake in Bangladesh-based RAK Paints.
ICICIBANK KANSAINER KNZAY 532174 IBN 500165

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...